香草防蚊 "蛙声阵阵，蝉鸣声声。"一年当中最热的时节登场了。夏至时节，骄阳似火，雨水频繁，人体皮肤 外露的时间明显延长，日晒损伤不说，蚊虫叮咬也令人不堪其扰。今天，中医科与皮肤科的医生就为大 家准备了一份护肤防蚊指南，请注意查收。 此外，还可外用炉甘石、薄荷脑、苯海拉明等止痒剂。若红肿明显，可适当冰敷，外用中效或弱效 激素类药物，如氢化可的松乳膏、糠酸莫米松乳膏等。 不过，若是局部有水疱或破溃，或者出现发热等不适，要及时到医院就诊。但最重要的提醒就是， 不要搔抓刺激。 食香养生 夏至属"火"，苦味食物有助降火。此时节，饮食配合苦菊、生菜等凉拌蔬菜，或饮用荷叶粥、绿豆 汤，能从内调节湿热体质。苦菊的微苦可清热泻火，生菜富含纤维助脾胃运化湿浊，荷叶粥借荷花的清 芳之气升发脾胃阳气，绿豆汤则是经典的解暑佳品。 夏季食物水分大，纤维含量高，而且很多自带芳香，清爽可口，就如同体内的"灭火剂"，当湿热之 邪随尿液排出，人体不再成为吸引蚊虫的"湿热温床"，自然也能减少叮咬困扰，让您安度盛夏。 古人有用香囊驱邪避秽的智慧，至今仍具妙用，可随身携带或放置居室中。取藿香、佩兰各10克， 橘皮、薄荷、豆蔻、丁香各5克，装入透气布袋 ...

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 中疾控专家：新冠感染的临床严重性未发生显著变化 在国家卫生健康委5月20日举行的新闻发布会上，中国疾控中心研究员安志杰表示，近期部分国家和地 区新冠疫情呈小幅上升趋势，但疾病的临床严重性没有发生显著变化。预防呼吸道传染病，在日常生活 中要保持良好个人卫生习惯，勤洗手，多通风；低龄儿童、老人及慢性病患者等免疫力较弱人群，建议 接种预防呼吸道传染病的相关疫苗。 药械审批 常山药那屈肝素钙注射液获得白俄罗斯药品注册证书 5月20日，步长制药（603858）公告，公司控股子公司浙江天元拟与辅必成(上海)医药科技有限公司就 MF59乳佐剂进行委托研发合作并签署委托研发协议。步长制药同日公告，为大力发展和整合公司大健 康产业，公司拟将持有的9家控股子公司(宁波步长贸易、山东步长药妆、山东步长鼎晟、山东步长传 方、山东步长优品、济南步长驰骋、济南步长财淦、济南步长瀛玺、济南步长众福)各1%股权转让给谢 继辉。谢继辉现任公司事业十七部总经理。 行业大事 上海医药利伐沙班片获得美国FDA批准文号 5月20日，上海医药（601 ...

Group 1 - Shanghai Pharmaceuticals has received FDA approval for its abbreviated new drug application (ANDA) for Rivaroxaban tablets [1] - Rivaroxaban is indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1][2] - The company has invested approximately RMB 8.2 million in the research and development of Rivaroxaban [1] Group 2 - The market for Rivaroxaban in the U.S. generated approximately $8.13 billion in sales in 2023, with projected sales of about $6.33 billion for the first three quarters of 2024 [2] - Competitors in the U.S. market for Rivaroxaban include Janssen Pharmaceuticals and several generic manufacturers [2] Group 3 - The FDA has also approved the ANDA for Mometasone Furoate nasal spray by Zhejiang Xinyi Ruijue Pharmaceutical [4] - Mometasone Furoate is used for the prevention and treatment of seasonal allergic rhinitis in adolescents and adults, as well as for chronic sinusitis with nasal polyps in adults [5] - The nasal spray generated approximately $43.7 million in sales in the U.S. in 2023, with projected sales of about $33.45 million for the first three quarters of 2024 [5]

编号：2025-003 | 投资者关系活动类别 | 特定对象调研 | | ☐分析师会议 | | | | | --- | --- | --- | --- | --- | --- | --- | | | ☐媒体采访 | | ☐业绩说明会 | | | | | | ☐新闻发布会 | | ☐路演活动 | | | | | | ☐现场参观 | | | 其他（投资者接待日） | | | | 参与单位名称及人员姓名 | 华创医药 | 王宏雨 | 慎知资产 | 高岳 | 湘财基金 | 张泉 | | | 大成基金 | 陈泉龙 | 兴全基金 | 张艺君 | 东方红 | 徐宏 | | | 博时基金 | 张之瑞 | 天风证券 | 刘一伯 | 中泰证券 | 祝嘉琪 | | | 招商证券 | 侯彪 | 开源医药 | 阮帅 | 华泰医药 | 李奕玮 | | | 华鲁投资 | 马宁科 | 中信建投 | 王云鹏 | 中信建投 | 赖俊勇 | | | 国盛医药 | 陶宸冉 | 杭银理财 | 王哲 | 天襄资本 | 杨一 | | | 东吴证券 | 俞昊岚 | 兴证医药 | 乔波耀 | 惠升基金 | 张政 | | | 华源证券 | 陶晨冉 | 西部 ...

随着气温升高，被称为"飞行硫酸"的隐翅虫进入活跃期。近日，医疗机构接诊的隐翅虫皮炎患者也多了起来，医生提醒，遇到隐翅虫千万不要拍打。 隐翅虫体色红黑相间，体液中含有称为毒隐翅虫素的酸性化合物，隐翅虫皮炎就是由这种物质导致的。 首都医科大学附属北京友谊医院皮肤性病科主任医师 王美芳：如果出现明显的红斑肿胀，建议用3%的硼酸溶液或者是0.1%的依沙吖啶溶液进行湿敷，每天 两次，每次15～20分钟。如果局部出现瘙痒，可以用一些激素药膏，譬如氢化可的松或者是糠酸莫米松，如果出现一些继发的感染，建议加一些外用的抗生 素。 防范隐翅虫 夏季关好纱窗 虽然隐翅虫身体含有毒素，碰到皮肤上会引起炎性反应，但是专家提醒公众不必恐慌，隐翅虫攻击性并不强。 隐翅虫，别称"影子虫""青腰虫"，外形像蚂蚁，但和蚂蚁不同的是，隐翅虫会飞。隐翅虫主要生活在农林田间，城市里的草丛、树林中也是隐翅虫的活动范 围。隐翅虫喜光，一到夜间，就会被灯光吸引。 一旦虫体被拍碎或受伤，毒液接触皮肤后会出现线状红斑、脓疱甚至糜烂等症状，因此隐翅虫也被称为"飞行的硫酸"。隐翅虫引发皮炎有明显季节性，一般 6月开始出现，8-9月是发病高峰期。 首都医科大学附属北 ...

Core Viewpoint - In 2024, the company achieved revenue of 4 billion yuan, a slight year-on-year decline, while net profit attributable to shareholders was significantly impacted by a fine related to sodium dexamethasone sales, with a stable growth in non-recurring net profit [1][2][3] - The impact of centralized procurement on the formulation segment has been largely digested, and new products are continuously being introduced, with expectations for accelerated growth in 2025 [1][4] - Revenue from the raw materials segment declined due to inventory destocking by overseas clients and price decreases, but sales volume remains stable, with a positive outlook for gradual recovery [1][5] Financial Performance - In 2024, the company reported operating revenue of 4.001 billion yuan, a year-on-year decrease of 2.98%, and a net profit attributable to shareholders of 397 million yuan, down 29.46% [2][3] - The non-recurring net profit for 2024 was 549 million yuan, reflecting a year-on-year increase of 2.15% [2][3] - For Q1 2025, the company achieved operating revenue of 1.01 billion yuan, a year-on-year decline of 2.9%, with a net profit of 140 million yuan, down 4.7% [2][3] Formulation Segment - In 2024, the formulation sales revenue reached 2.276 billion yuan, an increase of 8% year-on-year [4] - Key therapeutic areas showed varied performance, with gynecology and family planning sales at 450 million yuan, stable year-on-year; anesthetic muscle relaxants at 160 million yuan, up 55%; respiratory products at 880 million yuan, up 31%; and dermatology products at 230 million yuan, up 19% [4] - The company’s new products are expected to accelerate growth, with significant sales increases in new offerings such as sodium glucosamine injection [4][6] Raw Materials Segment - In 2024, revenue from raw materials and intermediates was 1.55 billion yuan, a year-on-year decline of 13% [5] - The decline was attributed to inventory destocking in the international market and increased competition leading to price drops [5][6] - The company is expected to see a recovery in the raw materials segment as prices stabilize and market share increases [5][6] Expense Analysis - In 2024, the company's sales, management, and R&D expense ratios were 25.84%, 7.74%, and 6.63%, respectively, with slight increases year-on-year [7] - The gross margin improved to 57.49%, up 4.61 percentage points, attributed to the clearing of centralized procurement impacts and operational efficiency [7] - The net profit margin was 10%, significantly impacted by a fine provision of 195 million yuan [7] Future Outlook - The company is expected to achieve stable growth in revenue and profit in 2025, with non-centralized procurement products anticipated to grow steadily [8] - Revenue projections for 2025-2027 are 4.35 billion, 4.81 billion, and 5.48 billion yuan, with year-on-year growth rates of 8.6%, 10.7%, and 13.8% respectively [8]

仙琚制药（688076.SH）2024 年年报及 2025 年一季报点评 短期业绩承压蓄势，新品迭代构建增长新范式 2025 年 04 月 28 日 ➢ 拆分：制剂业务收入维持稳健增长，原料药价格下探致使收入下滑。根据年报，公司 24 年制剂业务收入 24.2 亿元（同比+6.0%），毛利率 76.3%（同比+3.0pct）；原料药 业务收入 15.5 亿元（同比-13.4%），毛利率 28.9%（同比+2.7pct）。进一步拆分上看， 公司制剂业务增速放缓主要系普药和妇科两大业务线的相关品种纳入省级联盟集采（收入 端：普药同比-19.0%，妇科持平）；原料药业务收入下滑主要系非规市场价格下滑+规范 市场去库存等因素叠加（收入端：自营原料药同比-1.0%，意大利子公司-13.1%）。 ➢ 制剂：呼吸、皮肤稳健放量，麻醉肌松集采创伤后回暖。根据年报，公司 24 年自营 制剂产品收入 22.8 亿元，同比上升 8.0%。主要制剂产品收入按领域分拆来看，妇科计生 /麻醉肌松/呼吸/皮肤/普药实现收入 4.5/1.6/8.8/2.3/5.5 亿元，分别同比持平 /+55%/+31%/+19%/-19%。呼吸及皮肤成为 ...